Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00387868 · ClinicalTrials.gov registry record · Phase 2

Preoperative Treatment of Patients With High Risk Thymoma

A Phase 2 study, sponsored by Valley Health System.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target

NCT00387868 is a Phase 2 study that has completed, run by Valley Health System. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00387868, a Phase 2 study, has completed, sponsored by Valley Health System.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target

Study Summary

This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal. This study involves the use of combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the chances of complete resection. The chemoradiotherapy protocol is one which has been used extensively for other diseases, and the side effects are therefore well-documented. Patients with thymomas thought to be at significant risk for recurrence (by x-ray and pathology criteria) will be allowed to participate, and will undergo combined chemotherapy with radiation to the chest followed by surgical removal of the tumor and postoperative chemotherapy. The main outcome measured will be the rate of pathological complete response (e.g. no active tumor in the resected specimen) to the preoperative treatment. Patients will receive postoperative treatment based on surgical and pathologic criteria.

Interventions

  • PROCEDURE Surgical Resection
  • DRUG cisplatin and etoposide
  • RADIATION Concurrent Radiotherapy

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2006-10
Est. Completion 2014-11
Phase Phase 2

Sponsor

Valley Health System

8 total trials

What the Registry Record Tells You About NCT00387868

The ClinicalTrials.gov registry entry for NCT00387868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valley Health System, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Surgical Resection is the first listed.

NCT00387868 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00387868 about?

NCT00387868 is a clinical study titled "Preoperative Treatment of Patients With High Risk Thymoma". This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal. This study involves the use of combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the chances of complete resection. T...

What is the current status of trial NCT00387868?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-10. Estimated completion is 2014-11.

What interventions are being tested in trial NCT00387868?

The interventions under investigation include: Surgical Resection (PROCEDURE), cisplatin and etoposide (DRUG), Concurrent Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT00387868?

This trial is sponsored by Valley Health System, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.